The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
The icare4u program features a dedicated website, with comprehensive information about the diseases, videos with medical experts, and a social media community for patients and caregivers on Facebook and YouTube
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Quantib Prostate is an AI-based software solution that advances the MRI prostate reporting workflow and is accessible directly from the radiologist's reading station
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Subscribe To Our Newsletter & Stay Updated
